Show source-provided references
2. GBD 2021 Diabetes Collaborators (2023). Global, Regional, and National Burden of Diabetes from 1990 to 2021, with Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. Lancet, 402, 203–234.
3. World Health Organization (2024). Urgent Action Needed as Global Diabetes Cases Increase Four-Fold over Past Decades, WHO News Release.
4. Zhang, N., Qu, X., and Kang, L. (2025). Global, Regional and National Burden of Diabetes Mellitus Type 2 Attributable to Low Physical Activity from 1990 to 2021 and Projections to 2050: A Finding from the Global Burden of Disease Study 2021. Front. Clin. Diabetes Healthc., 6.
10.3389/fcdhc.2025.1606330 ↗7. A Review on Latent Autoimmune Diabetes in Adults
11. Double Diabetes: A Converging Metabolic and Autoimmune Disorder Redefining the Classification and Management of Diabetes
13. Unmet Needs in the Treatment of Type 1 Diabetes: Why Is It So Difficult to Achieve an Improvement in Metabolic Control?
10.1038/s41387-024-00319-w ↗14. Li, Y., Miao, Y., Feng, Q., Zhu, W., Chen, Y., Kang, Q., Wang, Z., Lu, F., and Zhang, Q. (2024). Mitochondrial Dysfunction and Onset of Type 2 Diabetes: A Multi-Omics Mendelian Randomization and Colocalization Study. Front. Endocrinol., 15.
10.3389/fendo.2024.1401531 ↗15. Mitochondrial Quality Control in Diabetes Mellitus and Complications: Molecular Mechanisms and Therapeutic Strategies
10.1038/s41419-025-07936-y ↗16. Molecular Aspects of Mitochondrial Dysfunction in Diabetes, Pearson and Kearns–Sayre Syndromes, and Neurodegenerative Disorders
10.2147/IJGM.S539967 ↗17. Iheagwam, F.N., Joseph, A.J., Adedoyin, E.D., Iheagwam, O.T., and Ejoh, S.A. (2025). Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight. Pathophysiology, 32.
10.3390/pathophysiology32010009 ↗18. PGC-1α, Inflammation, and Oxidative Stress: An Integrative View in Metabolism
19. AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies from Energy Homeostasis Regulation to Disease Therapy
10.1111/cns.70657 ↗21. Shrestha, N., De Franco, E., Arvan, P., and Cnop, M. (2021). Pathological β-Cell Endoplasmic Reticulum Stress in Type 2 Diabetes: Current Evidence. Front. Endocrinol., 12.
10.3389/fendo.2021.650158 ↗22. The Role of Endoplasmic Reticulum Stress in Type 2 Diabetes Mellitus Mechanisms and Impact on Islet Function
10.7717/peerj.19192 ↗23. Vilas-Boas, E.A., Almeida, D.C., Roma, L.P., Ortis, F., and Carpinelli, A.R. (2021). Lipotoxicity and β-Cell Failure in Type 2 Diabetes: Oxidative Stress Linked to NADPH Oxidase and ER Stress. Cells, 10.
10.3390/cells10123328 ↗24. Thomas, P., Gallagher, M.T., and Xavier, G.D.S. (2023). Beta Cell Lipotoxicity in the Development of Type 2 Diabetes: The Need for Species-Specific Understanding. Front. Endocrinol., 14.
10.3389/fendo.2023.1275835 ↗25. Lipotoxicity Induces β-Cell Small Extracellular Vesicle-Mediated β-Cell Dysfunction in Male Mice
10.1210/endocr/bqaf067 ↗26. Dhieb, D., Mustafa, D., Hassiba, M., Alasmar, M., Elsayed, M.H., Musa, A., Zirie, M., and Bastaki, K. (2025). Harnessing Pharmacomultiomics for Precision Medicine in Diabetes: A Comprehensive Review. Biomedicines, 13.
10.3390/biomedicines13020447 ↗27. Anwardeen, N.R., Naja, K., and Elrayess, M.A. (2024). Advancements in Precision Medicine: Multi-Omics Approach for Tailored Metformin Treatment in Type 2 Diabetes. Front. Pharmacol., 15.
10.3389/fphar.2024.1506767 ↗32. PROBAST+AI: An updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods
10.1136/bmj-2024-082505 ↗34. Guidelines for artificial intelligence in medicine: Literature review and content analysis of frameworks
10.2196/36823 ↗38. Vertex Pharmaceuticals Incorporated (2025, August 01). A Safety, Tolerability, and Efficacy Study of VX-880 in Participants with Type 1 Diabetes. ClinicalTrials.gov. Identifier: NCT04786262, Available online: https://clinicaltrials.gov/study/NCT04786262.
41. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
10.1136/bmj.n71 ↗43. Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress
10.4239/wjd.v14.i3.130 ↗49. Dobson, J.R., and Jacobson, D.A. (2024). Disrupted endoplasmic reticulum Ca2+ handling: A harbinger of β-cell failure. Biology, 13.
10.3390/biology13060379 ↗50. Zaher, A., and Stephens, S.B. (2025). Breaking the feedback loop of β-cell failure: Insight into the pancreatic β-cell’s ER–mitochondria redox balance. Cells, 14.
10.3390/cells14060399 ↗52. Yang, Y., and Cheng, H. (2024). Emerging roles of ncRNAs in type 2 diabetes mellitus: From mechanisms to drug discovery. Biomolecules, 14.
10.3390/biom14111364 ↗54. Chi, T., Lin, J., Wang, M., Zhao, Y., Liao, Z., and Wei, P. (2021). Non-coding RNA as biomarkers for type 2 diabetes development and clinical management. Front. Endocrinol., 12.
10.3389/fendo.2021.630032 ↗55. Circulating miRNA as potential biomarkers for diabetes mellitus type 2: Should we focus on searching for sex differences?
10.1007/s13353-021-00678-5 ↗56. Li, L., Wu, Y.-Q., and Yang, J.-E. (2025). Stress-related lncRNAs and their roles in diabetes and diabetic complications. Int. J. Mol. Sci., 26.
10.3390/ijms26052194 ↗57. Ke, L., Cao, Y., Lu, Z., and Hallajzadeh, J. (2024). Advances in different adult stem cell-derived exosomal non-coding RNAs for the treatment of neurological disorders: A narrative review. Front. Cell Dev. Biol., 12.
10.3389/fcell.2024.1459246 ↗60. Dinić, S., Arambašić Jovanović, J., Uskoković, A., Mihailović, M., Grdović, N., Tolić, A., Rajić, J., Đorđević, M., and Vidaković, M. (2022). Oxidative stress-mediated beta cell death and dysfunction as a target for diabetes management. Front. Endocrinol., 13.
10.3389/fendo.2022.1006376 ↗61. Role of oxidative stress in prediabetes development
63. Overcoming β-cell dysfunction in type 2 diabetes mellitus: CD36 inhibition and antioxidant system
10.4093/dmj.2024.0796 ↗66. Rosenbaum Emir, T.L. (2017). The role of TRP channels in the pancreatic beta-cell. Neurobiology of TRP Channels, Taylor & Francis. Chapter 12.
67. Liu, Y., Lyu, Y., and Wang, H. (2022). TRP channels as molecular targets to relieve endocrine-related diseases. Front. Mol. Biosci., 9.
10.3389/fmolb.2022.895814 ↗68. TRPM7 is a crucial regulator of pancreatic endocrine development and high-fat-diet-induced β-cell proliferation
10.1242/dev.194928 ↗72. Extracellular matrix stiffness mediates insulin secretion in pancreatic islets via mechanosensitive Piezo1 channel regulated Ca2+ dynamics
10.1016/j.mbplus.2024.100148 ↗73. Galli, A., Algerta, M., Marciani, P., Schulte, C., Lenardi, C., Milani, P., Maffioli, E., Tedeschi, G., and Perego, C. (2020). Shaping pancreatic β-cell differentiation and functioning: The influence of mechanotransduction. Cells, 9.
10.3390/cells9020413 ↗76. KATP channels and the metabolic regulation of insulin secretion in health and disease: The 2022 Banting Medal for Scientific Achievement Award Lecture
10.2337/dbi22-0030 ↗77. Rodríguez-Rivera, N.S., and Barrera-Oviedo, D. (2024). Exploring the pathophysiology of ATP-dependent potassium channels in insulin resistance. Int. J. Mol. Sci., 25.
10.20944/preprints202403.0502.v1 ↗78. Current understanding of KATP channels in neonatal diseases: Focus on insulin secretion disorders
10.1038/aps.2011.57 ↗79. A plasma membrane-associated glycolytic metabolon is functionally coupled to KATP channels in pancreatic α and β cells from humans and mice
10.1016/j.celrep.2023.112394 ↗81. Guan, G., Chen, Y., and Dong, Y. (2025). Unraveling the AMPK–SIRT1–FOXO pathway: The in-depth analysis and breakthrough prospects of oxidative stress-induced diseases. Antioxidants, 14.
10.3390/antiox14010070 ↗85. Kosgei, V.J., Coelho, D., Guéant-Rodriguez, R.M., and Guéant, J.-L. (2020). Sirt1-PPARS cross-talk in complex metabolic diseases and inherited disorders of the one carbon metabolism. Cells, 9.
10.3390/cells9081882 ↗86. Kiełbowski, K., Bakinowska, E., and Pawlik, A. (2025). Epigenetics plays a role in the pathogenesis and treatment of diabetes. Genes, 16.
10.3390/genes16070769 ↗87. Targeting the epigenetic marks in type 2 diabetes mellitus: Will epigenetic therapy be a valuable adjunct to pharmacotherapy?
10.2147/DMSO.S479077 ↗88. The impact of epigenetics on the pathophysiology of type 2 diabetes and associated nephropathic complications
10.4103/ijem.ijem_43_24 ↗89. Multiomics integration of epigenetics, proteomics, and metabolomics identifies putative drug targets and improves early prediction for diabetes
10.2337/db25-0354 ↗90. Liu, Y., Lei, Y., Dai, Z., Luo, C., Gong, Q., Li, Y., Xu, Y., and Huang, W. (2025). Trained immunity: Novel perspectives in diabetes and associated complications. Front. Immunol., 16.
10.3389/fimmu.2025.1613602 ↗91. Nițulescu, I.M., Ciulei, G., Cozma, A., Procopciuc, L.M., and Orășan, O.H. (2023). From innate immunity to metabolic disorder: A review of the NLRP3 inflammasome in diabetes mellitus. J. Clin. Med., 12.
10.3390/jcm12186022 ↗92. Karamitsos, K., Oikonomou, E., Theofilis, P., Ikonomidis, I., Kassi, E., Lambadiari, V., Gialafos, E., Tsatsaragkou, A., Mystakidi, V.-C., and Zisimos, K. (2025). The role of NLRP3 inflammasome in type 2 diabetes mellitus and its macrovascular complications. J. Clin. Med., 14.
10.3390/jcm14134606 ↗94. Chong, S., Lin, M., Chong, D., Jensen, S., and Lau, N.S. (2025). A systematic review on gut microbiota in type 2 diabetes mellitus. Front. Endocrinol., 15.
10.3389/fendo.2024.1486793 ↗95. The gut microbiota and diabetes: Research, translation, and clinical applications—2023 Expert Forum
99. Seo, H., Park, J.-H., Hwang, J.-T., Choi, H.-K., Park, S.-H., and Lee, J. (2023). Epigenetic profiling of type 2 diabetes mellitus: An epigenome-wide association study. Genes, 14.
10.3390/genes14122207 ↗